Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant<i>Streptococcus pneumoniae</i>: analysis of Phase 3 clinical trial data—authors' response: Figure 1.

Sir, Kirby1 comments on our publication2 that found clinical isolates of Streptococcus pneumoniae with azithromycin MICs of ≥2 mg/L, when compared with isolates with MICs of <0.5 mg/L, predict worse outcomes for patients receiving azithromycin to treat pneumococcal community-acquired respiratory tract infections (CARTIs). We determined that outcomes were not different for isolates with azithromycin MICs of 2–8, ≥16 or ≥64 mg/L.2 Kirby1 states that the relationship we observed between MIC and outcome for azithromycin-resistant isolates was not a linear dose (MIC)–response relationship. To improve the clarity of our data, we have graphically analysed the clinical cure rate as a function of azithromycin MIC for azithromycin-non-susceptible S. pneumoniae (Figure 1), treating MIC as a semi-continuous variable using all subjects eligible for analysis, including subjects with azithromycin-intermediate isolates. In the graphical analysis, if the MIC was recorded as ‘>X’, the numerical value was plotted as 2X; e.g. if the MIC was recorded as ‘>256 mg/L’, the value of the MIC plotted was 512 mg/L (Figure 1). Figure 1 depicts a linear relationship with clinical cure rates as a function of azithromycin MIC for all CARTI subjects with azithromycin-non-susceptible S. pneumoniae (MIC >0.5 mg/L; n = 124). The logistic regression model predicts no meaningful change in cure rate with increasing azithromycin MIC for subjects with CARTIs with azithromycin-non-susceptible S. pneumoniae. In our original publication we explained that the underlying reason for the apparently weak relationship between in vitro susceptibility and clinical cure rate (for azithromycin-non-susceptible S. pneumoniae) in patients treated with azithromycin could not be fully explained by the data available to us.2 We hypothesized that our observation may be due to a variety of reasons, including the unusual pharmacokinetic/pharmacodynamic properties of macrolides; specifically, that the azalide azithromycin is concentrated in tissues where CARTI occurs, as well as the reported ability of macrolides to exert immunomodulatory and anti-inflammatory effects. Kirby1 also suggests that a multivariate analysis is required to determine whether patient factors (e.g. age, comorbidities, previous episodes of RTI or macrolide treatment) may explain the observed association between azithromycin resistance and outcome in the treatment of S. pneumoniae RTI. Although it is difficult to argue that the results of additional analysis would not be helpful, the data were not available to perform such an analysis. That said, we do not believe that the results from such an analysis would have provided data that would change our original conclusion. As can be observed in Figure 1, there is a linear relationship between clinical cure rates and azithromycin MIC for all CARTI subjects with azithromycin-non-susceptible S. pneumoniae. This linear relationship has a small slope that may, or may not, become even flatter when patient factors are accounted for. The fact is, the line (relationship) is currently quite flat as it is. Logistic regression modelling of clinical cure rate for azithromycin-treated CARTI subjects with non-susceptible S. pneumoniae, as a function of azithromycin MIC. In closing, we do in part agree with Kirby1 that ‘MIC criteria defining resistance to azithromycin treatment of S. pneumoniae respiratory tract infections may be unhelpful in predicting an individual's risk of treatment failure’.1 When using oral azithromycin for the treatment of outpatient infections such as CARTI, the results of in vitro susceptibility testing may have limited clinical predictive value. K. D. W. is a full-time employee of Pfizer and owns Pfizer stock. Both other authors have none to declare.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.